Ernexa Therapeutics Inc. (ERNA)
NASDAQ: ERNA · Real-Time Price · USD
4.165
+0.145 (3.61%)
At close: Sep 11, 2026, 4:00 PM EDT
4.150
-0.015 (-0.36%)
After-hours: Sep 11, 2026, 7:57 PM EDT
Ernexa Therapeutics Employees
As of December 31, 2025, Ernexa Therapeutics had 7 total employees, including 5 full-time and 2 part-time employees. The number of employees increased by 1 or 16.67% compared to the previous year.
Employees
7
Change (1Y)
1
Growth (1Y)
16.67%
Revenue / Employee
n/a
Profits / Employee
-$1,753,429
Market Cap
6.80M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 7 | 1 | 16.67% | 5 | 2 |
| Dec 31, 2024 | 6 | -2 | -25.00% | 6 | 0 |
| Dec 31, 2023 | 8 | -1 | -11.11% | 8 | 0 |
| Dec 31, 2022 | 9 | -1 | -10.00% | 9 | 0 |
| Dec 31, 2021 | 10 | 0 | - | 10 | 0 |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| CollPlant Biotechnologies | 39 |
| Evogene | 38 |
| Bolt Biotherapeutics | 23 |
| AIM ImmunoTech | 21 |
| Cardio Diagnostics Holdings | 17 |
| Purple Biotech | 10 |
| Lexaria Bioscience | 7 |
| Enveric Biosciences | 6 |
ERNA News
- 17 days ago - Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference - GlobeNewsWire
- 4 weeks ago - Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage - GlobeNewsWire
- 7 weeks ago - Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies - GlobeNewsWire
- 2 months ago - Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry - GlobeNewsWire
- 2 months ago - Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026 - GlobeNewsWire
- 2 months ago - Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients - GlobeNewsWire
- 2 months ago - Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study - GlobeNewsWire
- 3 months ago - Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer - GlobeNewsWire